Identify health- and disease-associated microbial signatures and actionable biomarkers using advanced bioinformatics, machine learning, and microbiome data analysis.
Key Microbial Biomarker Detection is a specialized microbiome analysis service that identifies microbial species, genes, pathways, or microbial signatures associated with specific phenotypes, health conditions, treatment responses, or product performance. By analyzing complex microbiome datasets, BaseClear helps clients uncover biologically relevant biomarkers that can support scientific discovery, product development, diagnostics, patient stratification, and personalized interventions.
This service is designed for pharmaceutical companies, biotechnology organizations, academic researchers, food and nutrition companies, and healthcare innovators seeking to understand the relationship between microbial communities and biological outcomes. It is particularly valuable for projects involving disease association studies, clinical trials, probiotic development, microbiome-based product claims, therapeutic target discovery, and population-scale microbiome research.
BaseClear combines advanced sequencing technologies with sophisticated bioinformatics, statistics, and machine learning approaches to identify meaningful microbial biomarkers. Depending on the project objectives, analyses may include taxonomic profiling, functional metagenomics, differential abundance testing, pathway analysis, metadata integration, predictive modeling, and biomarker selection. Our multidisciplinary team of microbiologists, bioinformaticians, and data scientists works closely with clients to develop robust analytical strategies tailored to their research questions.
Clients receive a comprehensive set of deliverables, including quality-controlled sequencing data, validated biomarker candidates, statistical analyses, visualizations, and a detailed scientific report. Where applicable, results may include microbial signatures associated with specific phenotypes, predictive models, functional pathway insights, and recommendations for further validation or downstream research. This enables clients to move confidently from data generation to actionable biological insights.
Together, we define the biological question, study design, and desired outcome, such as disease biomarker discovery, treatment response prediction, or microbiome-based product development.
You provide microbiome samples and any relevant metadata, clinical information, or existing sequencing datasets. Our team reviews the inputs to ensure the analysis aligns with your research objectives.
BaseClear performs microbiome profiling and applies advanced bioinformatics, statistical analysis, and machine learning approaches to identify microbial signatures associated with your target phenotype or outcome.
Potential microbial biomarkers are evaluated based on statistical significance, biological relevance, and predictive value. The results are translated into clear insights that support scientific and commercial decision-making.
You receive a comprehensive report including biomarker candidates, visualizations, statistical results, and recommendations for validation or further research, enabling you to move confidently to the next stage of your project.
A research team investigating disease-associated microbiome signatures faced a common challenge in microbiome studies: different analytical methods often identify different biomarkers, making it difficult to distinguish true biological signals from statistical artifacts. The goal was to identify robust microbial biomarkers that remained predictive across independent datasets and disease populations.
BaseClear applied its ensemble microbial biomarker discovery framework, combining multiple statistical, machine learning, and feature-selection approaches into a single analysis pipeline. By integrating microbiome abundance profiles with clinical metadata and validating biomarker candidates across independent datasets, the framework increased the reliability and reproducibility of biomarker selection.
The analysis identified microbial signatures that consistently distinguished disease and control groups across multiple independent cohorts. Compared with individual analytical approaches, the ensemble methodology improved robustness and reproducibility, providing researchers with a higher-confidence set of microbial biomarkers for diagnostic, prognostic, and translational research applications.
End-to-end microbial safety assessment capabilities
Regulatory-ready data generation and interpretation
Integrated wet-lab and bioinformatics expertise
Structured support for EFSA and global submissions
BaseClear identifies robust microbial biomarkers using an ensemble analysis framework that combines multiple statistical and machine learning approaches. Rather than relying on a single method, the workflow integrates differential abundance analysis, feature selection, dimension reduction, and predictive modeling to identify microbial taxa that consistently associate with a specific phenotype, disease state, or treatment response. This approach improves reproducibility and reduces the risk of selecting biomarkers that are method-dependent.
Microbial biomarker discovery can be performed using both amplicon sequencing and shotgun metagenomics datasets. Taxonomic abundance tables generated from these workflows are combined with clinical, phenotypic, lifestyle, or study-specific metadata to identify associations between microbial communities and biological outcomes. The methodology is applicable to human, animal, food, environmental, and industrial microbiome studies.
BaseClear reduces false-positive biomarker identification by combining multiple analytical methods and validating candidate biomarkers across independent datasets whenever possible. Because different statistical approaches often produce different biomarker lists, the ensemble framework prioritizes biomarkers that remain significant across multiple analyses. This increases confidence that identified biomarkers reflect true biological signals rather than analytical artifacts.
Microbial biomarkers can be used to classify samples, stratify patient populations, and predict clinical outcomes. By applying machine learning algorithms to microbiome abundance data and metadata, BaseClear can identify microbial signatures that differentiate responders from non-responders, healthy and diseased populations, or distinct patient subgroups. These models can support diagnostics, personalized medicine, clinical trial design, and therapeutic development.
A microbial biomarker discovery project delivers validated biomarker candidates, statistical analyses, predictive model outputs, and comprehensive scientific reporting. Clients receive detailed visualizations, biomarker rankings, performance metrics and biological interpretation. These deliverables help researchers translate complex microbiome datasets into actionable biological insights and evidence-based decision making.
SERVICES
Phenotypic assessment of antimicrobial resistance aligned with EFSA guidelines
SERVICES
Phenotypic assessment of antimicrobial and cytotoxic production
Speak with our experts to design a WGS strategy aligned with your regulatory needs. Your first consultation is free and without obligation.
